Skip to main content
Prepare for an exciting September! Each week, we'll examine the latest trends in PAT, offering fresh insights straight from recent conferences. Your perspective matters, so we encourage you to share your thoughts as well. Stay informed, stay engaged, and let's explore these cutting-edge developments together. https://bit.ly/3Xw0X7k
18.188.30.94

7-Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir

By Ziegler, RE; Desai, BKJee, JA; Gupton, BF; Roper, TD; Jamison, TF

Published on CMKC

Abstract

Dolutegravir (DTG), an important active pharmaceutical ingredient (API) used in combination therapy for the treatment of HIV, has been synthesized in continuous flow. By adapting the reported GlaxoSmithKline process chemistry batch route for Cabotegravir, DTG was produced in 4.5h in sequential flow operations from commercially available materials. Key features of the synthesis include rapid manufacturing time for pyridone formation, one-step direct amidation of a functionalized pyridone, and telescoping of multiple steps to avoid isolation of intermediates and enable for greater throughput.


See also: Corrigendum: 7‐Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir - Ziegler - 2018 - Angewandte Chemie International Edition - Wiley Online Library

Journal

Angewandte Chemie International Edition. Volume 57, 2018, 7181-7185

DOI

10.1002/anie.201802256, 10.1002/anie.201809594

Type of publication

Peer-reviewed journal

Affiliations

  • Massachusetts Institute of Technology (MIT) (MIT)
  • Virginia Commonwealth University

Article Classification

Research Article

Classification Areas

  • API

Tags